Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CFD | P00746 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RGS12 | O14924 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954459 | 0.84 | NR4A2 (0.66) | FFAR1NR4A2LTB4RLTB4R2TSHR | |
| SCHEMBL957978 | 0.84 | SLC22A12 (0.68) | PPARDPLA2G4BFFAR1SLC22A12NR4A2 | |
| SCHEMBL955741 | 0.84 | PPARD (0.48) | PPARDPLA2G4BFFAR1SLC22A12NR4A2 | |
| SCHEMBL955388 | 0.81 | SLC22A12 (0.51) | PPARDPLA2G4BSLC22A12LTB4RLTB4R2 | |
| SCHEMBL25081992 | 0.80 | PLA2G4B (0.62) | PPARDPLA2G4BFFAR1LTB4RCYP4F2 | |
| SCHEMBL30278809 | 0.80 | PLA2G4B (0.62) | PPARDPLA2G4BFFAR1LTB4RCYP4F2 | |
| SCHEMBL7049768 | 0.79 | LMNA (0.62) | PPARDPLA2G4BFFAR1CYP4F2CYP4A11 | |
| SCHEMBL25081990 | 0.79 | PLA2G4B (0.68) | PPARDPLA2G4BFFAR1LTB4RCYP4F2 | |
| SCHEMBL25081989 | 0.79 | PLA2G4B (0.64) | PPARDPLA2G4BFFAR1LTB4RLTB4R2 | |
| SCHEMBL30278815 | 0.79 | PLA2G4B (0.68) | PPARDPLA2G4BFFAR1LTB4RCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947735-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-05-24 | — | — | US | claimed |
| CN-101374415-A | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORP (US) | 2009-02-25 | — | — | CN | claimed |
| US-20080306150-A1 | Compounds for the Treatment of Metabolic Disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-12-11 | — | — | US | claimed |
| EP-1976378-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-10-08 | — | — | EP | claimed |
| WO-2007087506-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-08-02 | — | — | WO | claimed |
| US-7947735-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-05-24 | — | — | US | disclosed |
| CN-101374415-A | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORP (US) | 2009-02-25 | — | — | CN | disclosed |
| US-20080306150-A1 | Compounds for the Treatment of Metabolic Disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1976378-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007087506-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306150-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FABP1, CPT1B | PPARD 243/4885PLA2G4B 3636/4885FFAR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.